CSE's Anil Mall was recently joined by Hugh Rogers, CEO of XPhyto Therapeutics Corp. (CSE:XPHY), to discuss how the "science-first" cannabis company prioritizes its focus on formulation, clinical validation, and emerging European markets.

In this discussion, Hugh shares how the company has built a "cultivation independent" operating philosophy that sidesteps the overhead associated with large cultivators (2:29), the newest pillar to their business focused on infectious disease screening (6:00), and the advantages that the company has by sticking firmly to their "science-first" mission (14:41).

Listen until the end to hear Hugh's insights into how he built his team through unique collaborations at the University of Alberta and the Technical University of Munich!

🔴 Subscribe for more great CSE insights and interviews here: https://go.thecse.com/CSETV-Subscribe

#alwaysinvested

STAY CONNECTED WITH THE CSE
=============================

📧 - NEWSLETTER: https://go.thecse.com/CSE-Mailing-List-Subscribe
🎧 - PODCAST: https://blog.thecse.com/cse-podcasts/
📸 - INSTAGRAM: https://www.instagram.com/canadianexchange/
🤝 - LINKEDIN: https://ca.linkedin.com/company/canadian-securities-exchange
👥 - FACEBOOK: https://www.facebook.com/CanadianSecuritiesExchange/
🐦 - X: https://x.com/CSE_News
📝 - BLOG: https://blog.thecse.com/
🖥 - WEBSITE: https://thecse.com/
📖 - MAGAZINE: https://issuu.com/thecse/docs

©2024 CNSX Markets Inc. All rights reserved.